Blueprint Medicines Lands $40,000,000 Series A Financing Round

  • Feed Type
  • Date
    4/11/2011
  • Company Name
    Blueprint Medicines
  • Mailing Address
    Undisclosed Cambridge, MA 02138
  • Company Description
    Blueprint Medicines is driving the development of personalized, highly-selective cancer therapies that harness the growing understanding of the molecular blueprint of cancer.
  • Website
    http://www.blueprintmedicines.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $40,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds from the financing will be used to develop new cancer therapies – using the company’s proprietary compound library and Insights-to-Validation™ Platform – that target the driver molecular aberrations of cancer and emerging resistance mechanisms unique to certain cancer patients.
  • M&A Terms
  • Venture Investor
    Third Rock Ventures
  • Venture Investor
    Third Rock Ventures
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.